Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture.
Genetic modification of hematopoietic stem cells with a synthetic "anti-human immunodeficiency virus type 1 (HIV-1) gene" which inhibits replication of HIV-1 may allow production of mature lymphoid and monocytic cells resistant to HIV-1 growth after autologous transplantation. Because productive HIV-1 replication requires binding of the Rev protein to the Rev-responsive element (RRE) within the viral transcripts for the HIV-1 structural proteins, anti-HIV-1 gene products which interfere with Rev-RRE interactions may inhibit HIV-1 replication. One such strategy involves overexpression of the RRE sequences in transcripts derived from retroviral vectors to act as decoys to sequester Rev protein and prevent its binding to the RRE element in HIV-1 transcripts. We developed an in vitro model to test the efficacy of this gene therapy approach in primary human hematopoietic cells. Human CD34+ hematopoietic progenitor cells from normal bone marrow or umbilical cord blood were transduced with retroviral vectors carrying RRE decoy sequences as part of a long terminal repeat-directed transcript expressing the neo gene (L-RRE-neo) or with a control vector expressing only the neo gene (LN). The transduced progenitors were allowed to differentiate into mature myelomonocytic cells which were able to support vigorous growth of the monocytotropic isolate of HIV-1, JR-FL. HIV-1 replication was measured in unselected cell populations and following G418 selection to obtain uniformly transduced cell populations. Inhibition of HIV-1 replication in the unselected cell cultures was between 50.2 and 76.7% and was highly effective (99.4 to 99.9%) in the G418-selected cultures. Progenitors transduced by either the L-RRE-neo vector or the control LN vector were identical with respect to hematopoietic growth and differentiation. These findings demonstrate the ability of an RRE decoy strategy to inhibit HIV-1 replication in primary human myelomonocytic cells after transduction of CD34+ progenitor cells, without adverse effects on hematopoietic cell function.
Bahner
I
I
Department of Pediatrics, University of Southern California School of Medicine, California 90027, USA.
Kearns
K
K
Hao
Q L
QL
Smogorzewska
E M
EM
Kohn
D B
DB
D016475:3T3 Cells; D000818:Animals; D018952:Antigens, CD34; D001483:Base Sequence; D002454:Cell Differentiation; D002455:Cell Division; D002478:Cells, Cultured; D015694:Gene Products, rev / Q000037:antagonists & inhibitors / Q000378:metabolism*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D016655:HIV Core Protein p24 / Q000096:biosynthesis; D015497:HIV-1 / Q000378:metabolism / Q000502:physiology*; D006412:Hematopoietic Stem Cells / Q000276:immunology / Q000821:virology; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D012367:RNA, Viral; D013601:T-Lymphocytes / Q000166:cytology / Q000821:virology; D014779:Virus Replication / Q000235:genetics; D054321:rev Gene Products, Human Immunodeficiency Virus
D018952:Antigens, CD34; D015694:Gene Products, rev; D016655:HIV Core Protein p24; D012367:RNA, Viral; D054321:rev Gene Products, Human Immunodeficiency Virus